Compare Stocks: AQB, PDSB, LGVN, and LTRN

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AQB AquaBounty Technologies	$1.14 +0.9%	$1.14	$0.77 ▼ $2.95	$5.87M	1.45	41,523 shs	30,562 shs
LGVN Longeveron	$2.49 -8.1%	$6.75	$2.30 ▼ $12.30	$7.94M	-0.25	147,048 shs	522,834 shs
LTRN Lantern Pharma	$1.55 -9.4%	$2.41	$1.11 ▼ $4.70	$19.82M	2.3	161,755 shs	190,154 shs
PDSB PDS Biotechnology	$0.81 -4.4%	$0.49	$0.20 ▼ $1.55	$45.08M	1.46	61.36 million shs	18.84 million shs

7 Energy Stocks to Buy and Hold Forever

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AQB AquaBounty Technologies	0.00%	-6.56%	-12.98%	+21.28%	0.00%
LGVN Longeveron	0.00%	-66.03%	-69.93%	-69.64%	-66.84%
LTRN Lantern Pharma	0.00%	-9.36%	-32.31%	-58.51%	-60.36%
PDSB PDS Biotechnology	0.00%	+173.14%	+285.59%	-15.65%	-29.96%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AQB AquaBounty Technologies	$1.14 +0.9%	$1.14	$0.77 ▼ $2.95	$5.87M	1.45	41,523 shs	30,562 shs
LGVN Longeveron	$2.49 -8.1%	$6.75	$2.30 ▼ $12.30	$7.94M	-0.25	147,048 shs	522,834 shs
LTRN Lantern Pharma	$1.55 -9.4%	$2.41	$1.11 ▼ $4.70	$19.82M	2.3	161,755 shs	190,154 shs
PDSB PDS Biotechnology	$0.81 -4.4%	$0.49	$0.20 ▼ $1.55	$45.08M	1.46	61.36 million shs	18.84 million shs

7 Energy Stocks to Buy and Hold Forever

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AQB AquaBounty Technologies	0.00%	-6.56%	-12.98%	+21.28%	0.00%
LGVN Longeveron	0.00%	-66.03%	-69.93%	-69.64%	-66.84%
LTRN Lantern Pharma	0.00%	-9.36%	-32.31%	-58.51%	-60.36%
PDSB PDS Biotechnology	0.00%	+173.14%	+285.59%	-15.65%	-29.96%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AQB AquaBounty Technologies	1.00	Sell	N/A	N/A
LGVN Longeveron	2.00	Hold	$80.00	3,112.85% Upside
LTRN Lantern Pharma	1.00	Sell	N/A	N/A
PDSB PDS Biotechnology	2.33	Hold	$9.00	1,017.32% Upside

Current Analyst Ratings Breakdown

Latest AQB, PDSB, LGVN, and LTRN Analyst Ratings

Date	Company	Brokerage	Action	Rating
9/14/2026	AQB AquaBounty Technologies	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
9/11/2026	PDSB PDS Biotechnology	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
9/8/2026	LGVN Longeveron	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
8/28/2026	AQB AquaBounty Technologies	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
8/26/2026	PDSB PDS Biotechnology	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
8/25/2026	LGVN Longeveron	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
8/14/2026	PDSB PDS Biotechnology	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
8/12/2026	AQB AquaBounty Technologies	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
8/11/2026	LGVN Longeveron	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
7/29/2026	LTRN Lantern Pharma	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
7/28/2026	LGVN Longeveron	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)

(Data available from 9/20/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AQB AquaBounty Technologies	$2.47M	2.38	N/A	N/A	($0.49) per share	-2.33
LGVN Longeveron	$1.19M	6.69	N/A	N/A	$2.47 per share	1.01
LTRN Lantern Pharma	N/A	N/A	N/A	N/A	$0.58 per share	N/A
PDSB PDS Biotechnology	N/A	N/A	N/A	N/A	$0.18 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AQB AquaBounty Technologies	-$18.49M	-$0.82	N/A	N/A	N/A	N/A	-147.07%	-28.73%	11/10/2026 (Estimated)
LGVN Longeveron	-$22.70M	-$9.90	N/A	N/A	N/A	-1,977.59%	-223.19%	-150.20%	11/3/2026 (Estimated)
LTRN Lantern Pharma	-$17.12M	-$1.62	N/A	N/A	N/A	N/A	-368.02%	-148.62%	11/11/2026 (Estimated)
PDSB PDS Biotechnology	-$34.50M	-$0.64	N/A	N/A	N/A	N/A	-708.18%	-136.50%	11/12/2026 (Estimated)

Latest AQB, PDSB, LGVN, and LTRN Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2026	Q2 2026	LTRN Lantern Pharma	-$0.38	-$0.57	-$0.19	-$0.57	N/A	N/A
8/13/2026	Q2 2026	PDSB PDS Biotechnology	-$0.13	-$0.18	-$0.05	-$0.18	N/A	N/A
8/12/2026	Q2 2026	LGVN Longeveron	-$1.75	-$1.90	-$0.15	-$0.19	$0.33 million	$0.29 million
8/6/2026	Q2 2026	AQB AquaBounty Technologies	N/A	-$0.26	N/A	-$0.32	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
AQB AquaBounty Technologies	N/A	N/A	N/A	N/A	N/A
LGVN Longeveron	N/A	N/A	N/A	N/A	N/A
LTRN Lantern Pharma	N/A	N/A	N/A	N/A	N/A
PDSB PDS Biotechnology	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AQB AquaBounty Technologies	N/A	4.26	4.26
LGVN Longeveron	N/A	2.63	2.63
LTRN Lantern Pharma	N/A	1.96	1.96
PDSB PDS Biotechnology	2.73	0.57	0.57

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AQB AquaBounty Technologies	8.92%
LGVN Longeveron	10.01%
LTRN Lantern Pharma	28.62%
PDSB PDS Biotechnology	26.84%

Insider Ownership

Company	Insider Ownership
AQB AquaBounty Technologies	1.02%
LGVN Longeveron	7.42%
LTRN Lantern Pharma	8.50%
PDSB PDS Biotechnology	8.40%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AQB AquaBounty Technologies	100	5.15 million	5.10 million	No Data
LGVN Longeveron	38	3.19 million	2.95 million	Not Optionable
LTRN Lantern Pharma	16	12.78 million	11.70 million	Optionable
PDSB PDS Biotechnology	21	55.97 million	51.27 million	Optionable

AQB, PDSB, LGVN, and LTRN Headlines

Recent News About These Companies

PDS Biotechnology (NASDAQ:PDSB) Upgraded at Wall Street Zen

September 19 at 1:13 AM | americanbankingnews.com

PDS Biotechnology (PDSB) Stock Fair Value Moves Lower After Analyst Cuts And Financing Scrutiny

September 18 at 11:59 PM | finance.yahoo.com

PDS Biotechnology Reports Initial Closing of Private Financing

September 16, 2026 | finance.yahoo.com

Biotech Stocks Gain Ground: PDS Biotech, Clene, Indaptus Lead Movers

September 15, 2026 | rttnews.com

PDS Biotechnology jumps as investors react to PIPE closing and Patrick Soon-Shiong tie-up

September 15, 2026 | quiverquant.comQ

PDS Biotechnology consensus price target decreased by 13.79% to $4.25

September 15, 2026 | msn.com

IBRX Stock Gains As Soon-Shiong’s Nant Capital Backs Second Cancer-Immunotherapy Bet

September 15, 2026 | msn.com

PDS Biotech Announces Initial Closing of up to $22.3 Million PIPE Financing and the Appointment of Dr. Patrick Soon-Shiong to Its Board of Directors

September 14, 2026 | finance.yahoo.com

PDS Biotechnology Raises $11.3 Million in Initial Closing of PIPE Led by Nant Capital; Dr. Soon-Shiong Joins Board

September 14, 2026 | quiverquant.comQ

PDS Biotech Announces Initial Closing of up to $22.3 Million PIPE Financing and the Appointment of Dr. Patrick Soon-Shiong to Its Board of Directors

September 14, 2026 | globenewswire.com

FY2026 EPS Estimate for PDS Biotechnology Reduced by Analyst

September 13, 2026 | americanbankingnews.com

Stock Traders Buy Large Volume of PDS Biotechnology Call Options (NASDAQ:PDSB)

September 10, 2026 | americanbankingnews.com

PDS Biotech Raises Up To $22.55M In PIPE Led By Dr. Patrick Soon-Shiong

September 8, 2026 | rttnews.com

PDS Biotechnology Raises $22.6 Million in Equity Funding; Shares Rise

September 8, 2026 | finance.yahoo.com

PDS Biotech Jumps as Soon-Shiong-Backed Financing Eases Funding Pressure

September 8, 2026 | quiverquant.comQ

PDS Biotech soars as it announces up to $22.55 million financing

September 8, 2026 | thepharmaletter.comT

PDS Biotech Announces up to $22.55 Million Financing Led by Dr. Patrick Soon-Shiong, Founder of NantWorks

September 8, 2026 | globenewswire.com

PDS Biotechnology Corporation: PDS Biotech Reports Second Quarter 2026 Financial Results

August 13, 2026 | finanznachrichten.de

PDS Biotech Reports $9.8 Million Second-Quarter 2026 Net Loss

August 13, 2026 | quiverquant.comQ

PDS Biotech Reports Second Quarter 2026 Financial Results

August 13, 2026 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

AQB, PDSB, LGVN, and LTRN Company Descriptions

AquaBounty Technologies NASDAQ:AQB

$1.14 +0.01 (+0.88%)

As of 09/18/2026 04:00 PM Eastern

AquaBounty Technologies, Inc., a biotechnology company, operates in the aquaculture industry in the United States and Canada. The company engages in genetic, genomic, and fish health and nutrition research activities. It also operates salmon farms using proprietary technology. In addition, the company offers AquAdvantage Salmon, a genetically engineered Atlantic salmon for human consumption; and sells conventional Atlantic salmon, salmon eggs, fry, and byproducts. The company was formerly known as Aqua Bounty Farms, Inc. and changed its name to AquaBounty Technologies, Inc. in June 2004. AquaBounty Technologies, Inc. was incorporated in 1991 and is headquartered in Harvard, Massachusetts.

Longeveron NASDAQ:LGVN

$2.49 -0.22 (-8.12%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$2.51 +0.02 (+0.80%)

As of 09/18/2026 07:48 PM Eastern

Longeveron Inc., a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions in the United States and Japan. The company's lead investigational product is the LOMECEL-B, an allogeneic mesenchymal stem cell formulation sourced from the bone marrow of young and healthy adult donors. It is conducting Phase 1, Phase 1/2, Phase 2a, and Phase 2b clinical trials in various indications, such as aging-related frailty, alzheimer's disease, and hypoplastic left heart syndrome. Longeveron Inc. was incorporated in 2014 and is headquartered in Miami, Florida.

Lantern Pharma NASDAQ:LTRN

$1.55 -0.16 (-9.36%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$1.63 +0.08 (+5.16%)

As of 09/18/2026 07:41 PM Eastern

Lantern Pharma Inc., a clinical stage biotechnology company, focuses on artificial intelligence, machine learning, and genomic data to streamline the drug development process. Its product pipeline comprises LP-300, which is in phase 2 clinical trial in combination therapy for never-smokers with non-small cell lung cancer adenocarcinoma; LP-184, which is in phase 1 clinical trial for the treatment of solid tumor, such as pancreatic, breast, bladder, and lung cancers, and glioblastoma and other central nervous system cancers; and LP-284, which is in phase 1 clinical trial for the treatment of non-Hodgkin's lymphomas, including mantle cell lymphoma and double hit lymphoma. The company develops STAR-001, which is in preclinical development for the treatment of glioblastoma, brain metastases, atypical teratoid rhabdoid tumors, and pediatric rare disease designation. In addition, it provides ADC program, an antibody drug conjugate therapeutic approach for cancer treatment. Further, the company's artificial intelligence platform RADR uses big data analytics and machine learning for combining molecular data. Lantern Pharma Inc. has a strategic AI-driven collaboration with Oregon Therapeutics to optimize the development of its first-in-class protein disulfide isomerase inhibitor drug candidate XCE853 in novel and targeted cancer indications. The company was incorporated in 2013 and is headquartered in Dallas, Texas.

PDS Biotechnology NASDAQ:PDSB

$0.81 -0.04 (-4.36%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$0.83 +0.02 (+2.55%)

As of 09/18/2026 07:59 PM Eastern

PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, developing a pipeline of targeted cancer immunotherapies in the United States. The company's lead product candidate is PDS0101 (HPV16), which is in Phase II clinical trial provides a first line treatment for the recurrent/metastatic head and neck cancer, and human papillomavirus associated malignancies. It also develops various product candidates, which are in preclinical trials, including PDS0102, an investigational immunotherapy utilizing tumor-associated and immunologically active T cell receptor gamma alternate reading framed protein (TARP) for treating prostate and breast cancers; and PDS0103 for ovarian, colorectal, lung, and breast cancers. In addition, the company is developing PDS01ADC, a novel investigational Interleukin 12 fused antibody-drug conjugate that enhances the proliferation, potency, and longevity of T cells in the tumor microenvironment; and PDS0104, a novel investigational Tyrosinase-related Protein 2 targeted immunotherapy that stimulates a potent targeted T cell attack against melanoma. Further, the company provides PDS0202, a novel investigational influenza vaccine that generates broad and robust antibody and T cell responses that provide protection against continually evolving strains of seasonal flu and potentially emerging pandemic flu. It has a license and collaboration agreements with National Institutes of Health, Merck Eprova AG, The U.S. Department of Health and Human Services, and MSD International GmbH. The company was founded in 2005 and is based in Princeton, New Jersey.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest AQB, PDSB, LGVN, and LTRN Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest AQB, PDSB, LGVN, and LTRN Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

AQB, PDSB, LGVN, and LTRN Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

AQB, PDSB, LGVN, and LTRN Company Descriptions

AquaBounty Technologies NASDAQ:AQB

Longeveron NASDAQ:LGVN

Lantern Pharma NASDAQ:LTRN

PDS Biotechnology NASDAQ:PDSB

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest AQB, PDSB, LGVN, and LTRN Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest AQB, PDSB, LGVN, and LTRN Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

AQB, PDSB, LGVN, and LTRN Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

AQB, PDSB, LGVN, and LTRN Company Descriptions

AquaBounty Technologies NASDAQ:AQB

Longeveron NASDAQ:LGVN

Lantern Pharma NASDAQ:LTRN

PDS Biotechnology NASDAQ:PDSB

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools